Literature DB >> 21997398

Genetic variation in APOL1 associates with younger age at hemodialysis initiation.

Zahra Kanji1, Camille E Powe, Julia B Wenger, Chunmei Huang, Elizabeth Ankers, Dorothy A Sullivan, Gina Collerone, Neil R Powe, Marcello Tonelli, Ishir Bhan, Andrea J Bernhardy, Salvatore Dibartolo, David Friedman, Giulio Genovese, Martin R Pollak, Ravi Thadhani.   

Abstract

African Americans have a markedly higher incidence of ESRD compared with other racial groups. Two variants in the APOL1 gene, to date observed only among individuals of recent African ancestry, associate with increased risk for renal disease among African Americans. Here, we investigated whether these risk alleles also associate with age at initiation of chronic hemodialysis. We performed a cross-sectional study of 407 nondiabetic African Americans with ESRD who participated in the Accelerated Mortality on Renal Replacement (ArMORR) study, a prospective cohort of incident chronic hemodialysis patients. African Americans carrying two copies of the G1 risk allele initiated chronic hemodialysis at a mean age of 49.0 ± 14.9 years, which was significantly younger than both subjects with one copy of the G1 allele (55.9 ± 16.7 years; P = 0.014) and subjects without either risk allele (61.8 ± 17.1 years; P = 6.2 × 10(-7)). The association between the presence of the G1 allele and age at initiation of hemodialysis remained statistically significant after adjusting for sociodemographic and other potential confounders. We did not detect an association between the G2 risk allele and age at initiation of hemodialysis, but the sample size was limited. In conclusion, genetic variations in APOL1 identify African Americans that initiate chronic hemodialysis at a younger age. Early interventions to prevent progression of kidney disease may benefit this high-risk population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997398      PMCID: PMC3231784          DOI: 10.1681/ASN.2010121234

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  15 in total

1.  Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors.

Authors:  Michelle E Tarver-Carr; Neil R Powe; Mark S Eberhardt; Thomas A LaVeist; Raynard S Kington; Josef Coresh; Frederick L Brancati
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

2.  Neighborhood poverty and racial differences in ESRD incidence.

Authors:  Nataliya Volkova; William McClellan; Mitchel Klein; Dana Flanders; David Kleinbaum; J Michael Soucie; Rodney Presley
Journal:  J Am Soc Nephrol       Date:  2007-12-05       Impact factor: 10.121

3.  End-stage renal disease in African-American and white men. 16-year MRFIT findings.

Authors:  M J Klag; P K Whelton; B L Randall; J D Neaton; F L Brancati; J Stamler
Journal:  JAMA       Date:  1997 Apr 23-30       Impact factor: 56.272

4.  Family history of end-stage renal disease among incident dialysis patients.

Authors:  B I Freedman; J M Soucie; W M McClellan
Journal:  J Am Soc Nephrol       Date:  1997-12       Impact factor: 10.121

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  The timing of specialist evaluation in chronic kidney disease and mortality.

Authors:  Kraig S Kinchen; John Sadler; Nancy Fink; Ronald Brookmeyer; Michael J Klag; Andrew S Levey; Neil R Powe
Journal:  Ann Intern Med       Date:  2002-09-17       Impact factor: 25.391

7.  Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States.

Authors:  Chi-Yuan Hsu; Feng Lin; Eric Vittinghoff; Michael G Shlipak
Journal:  J Am Soc Nephrol       Date:  2003-11       Impact factor: 10.121

8.  MYH9 is associated with nondiabetic end-stage renal disease in African Americans.

Authors:  W H Linda Kao; Michael J Klag; Lucy A Meoni; David Reich; Yvette Berthier-Schaad; Man Li; Josef Coresh; Nick Patterson; Arti Tandon; Neil R Powe; Nancy E Fink; John H Sadler; Matthew R Weir; Hanna E Abboud; Sharon G Adler; Jasmin Divers; Sudha K Iyengar; Barry I Freedman; Paul L Kimmel; William C Knowler; Orly F Kohn; Kristopher Kramp; David J Leehey; Susanne B Nicholas; Madeleine V Pahl; Jeffrey R Schelling; John R Sedor; Denyse Thornley-Brown; Cheryl A Winkler; Michael W Smith; Rulan S Parekh
Journal:  Nat Genet       Date:  2008-09-14       Impact factor: 38.330

9.  Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group.

Authors:  W G Walker; J D Neaton; J A Cutler; R Neuwirth; J D Cohen
Journal:  JAMA       Date:  1992-12-02       Impact factor: 56.272

10.  Vitamin D levels and early mortality among incident hemodialysis patients.

Authors:  M Wolf; A Shah; O Gutierrez; E Ankers; M Monroy; H Tamez; D Steele; Y Chang; C A Camargo; M Tonelli; R Thadhani
Journal:  Kidney Int       Date:  2007-08-08       Impact factor: 10.612

View more
  53 in total

1.  The new era of APOL1-associated glomerulosclerosis.

Authors:  Barry I Freedman; Carl D Langefeld
Journal:  Nephrol Dial Transplant       Date:  2012-02-02       Impact factor: 5.992

2.  Race, Relationship and Renal Diagnoses After Living Kidney Donation.

Authors:  Krista L Lentine; Mark A Schnitzler; Amit X Garg; Huiling Xiao; David Axelrod; Janet E Tuttle-Newhall; Daniel C Brennan; Dorry L Segev
Journal:  Transplantation       Date:  2015-08       Impact factor: 4.939

3.  APOL1 variants and kidney disease in people of recent African ancestry.

Authors:  Giulio Genovese; David J Friedman; Martin R Pollak
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

Review 4.  APOL1 and nephropathy progression in populations of African ancestry.

Authors:  Barry I Freedman
Journal:  Semin Nephrol       Date:  2013-09       Impact factor: 5.299

5.  Genes, Exomes, Genomes, Copy Number: What is Their Future in Pediatric Renal Disease.

Authors:  Matthew G Sampson; Harald Jüppner
Journal:  Curr Pediatr Rep       Date:  2012-12-22

6.  APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans.

Authors:  Alex N Kasembeli; Raquel Duarte; Michèle Ramsay; Pulane Mosiane; Caroline Dickens; Thérèse Dix-Peek; Sophie Limou; Efe Sezgin; George W Nelson; Agnes B Fogo; Stewart Goetsch; Jeffrey B Kopp; Cheryl A Winkler; Saraladevi Naicker
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

7.  Effect of Genetic African Ancestry on eGFR and Kidney Disease.

Authors:  Miriam S Udler; Girish N Nadkarni; Gillian Belbin; Vaneet Lotay; Christina Wyatt; Omri Gottesman; Erwin P Bottinger; Eimear E Kenny; Inga Peter
Journal:  J Am Soc Nephrol       Date:  2014-10-27       Impact factor: 10.121

Review 8.  Hypertension and chronic kidney disease: controversies in pathogenesis and treatment.

Authors:  J L Pirkle; B I Freedman
Journal:  Minerva Urol Nefrol       Date:  2013-03       Impact factor: 3.720

Review 9.  Clinical Genetic Testing for APOL1: Are we There Yet?

Authors:  Bessie A Young; Stephanie Malia Fullerton; James G Wilson; Kerri Cavanaugh; Erika Blacksher; Clarence Spigner; Jonathan Himmelfarb; Wylie Burke
Journal:  Semin Nephrol       Date:  2017-11       Impact factor: 5.299

10.  Plasma apolipoprotein L1 levels do not correlate with CKD.

Authors:  Leslie A Bruggeman; John F O'Toole; Michael D Ross; Sethu M Madhavan; Marlene Smurzynski; Kunling Wu; Ronald J Bosch; Samir Gupta; Martin R Pollak; John R Sedor; Robert C Kalayjian
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.